One glaring omission was that in previous presentations, Don said both TNBC and mCRPC were possibly registration enabling studies.

Well, TNBC has been abandoned as we all know.

And he notably did not mention this for mCRPC.

I wondered if this was a case of "pretend the thing we said before doesn't exist and leave shareholders wondering". Kind of a modus operandi for this man.

So looking at the recent MD&A I see this:

The first patient in this study was dosed in December 2021 and to date approximately 120 patients have been dosed. Interim data from this trial is expected to readout in late 2024 or early 2025 based on study accrual. The trial is powered to show an improvement of radiographic progression free survival of 67% compared to single agent enzalutamide. If the trial’s endpoint is met, we will discuss with the FDA advancing the program to a registration enabling Phase 3 randomized study.

Honestly I don't know why I bother listening to these presentations. Narmac had it right, they only serve to mislead.